Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-29T14:52:05.581Z Has data issue: false hasContentIssue false
  • English
  • Français

The continued evolution of team science

Published online by Cambridge University Press:  12 April 2017

Harry P. Selker
Harry P. Selker*
Affiliation:
President, ACTS Chairman, Clinical Research Forum Dean, Tufts Clinical and Translational Science Institute
*
*Address for correspondence: Harry P. Selker, M.D., M.S.P.H., President, ACTS; Dean, Tufts Clinical and Translational Science Institute, Tufts University; Executive Director, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St., #63, Boston, MA 02111. (Email: [email protected])
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
President’s Message
Information
Journal of Clinical and Translational Science , Volume 1 , Issue 1 , February 2017 , pp. 7
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited
Copyright
© The Association for Clinical and Translational Science 2017

Introduction

A decade ago, National Institutes of Health (NIH) Director, Elias Zerhouni proposed NIH Clinical and Translational Science Awards (CTSAs) as “homes for clinical and translational science” at their host institutions. This has been an important success of the past decade, but insufficient to accomplish the stated goal to accelerate and improve the quality and impact of research in service of the public’s health.

CTSAs are no longer only primarily directed at creating institutional homes for translational science—that is just a baseline condition. Now CTSAs and other clinical and translational research enterprises are expected to support the capabilities of, and create the conditions for, studies that are relevant and impactful—studies that are responsive to the needs of patients and the public. With crucial nudging from patient-advocacy groups and foundations, and the Patient-Centered Outcomes Research Institute, the bar for broadening inclusion in the planning and execution of research has been raised. We have come to understand that, from inception through completion and dissemination of results, research must have input from intended partners, participants, and beneficiaries. As outlined in the following article, we see this as an evolution of “team science.” With great respect for the hallowed and evolving community-engaged research model, we want to more fully represent the need to authentically include stakeholders, communities, and the broad public as members of the research team: “broadly engaged team science.”

As researchers and leaders of research, members of ACTS and Clinical Research Forum depend on public and individual resources, engagement, and trust. In return, it is incumbent on us to execute research in the public’s interest. This requires application of the best scientific methods, wisely and efficiently—and it also requires engaging the public in new and novel ways. Not only will this generate better and more widely-applicable research, hopefully it will also catalyze a change in how the public regards science, the role of government, the roles of citizenship, and our common mission as members of society.